International Journal of Advanced Research in Biological Sciences
ISSN: 2348-8069
www.ijarbs.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijarbs Coden: IJARQG (USA) Volume 10, Issue12-2023

Review Article

DOI: http://dx.doi.org/10.22192/ijarbs.2023.10.12.007

# Safety and Efficacy of Dredger Revascularization Device: A Clinical Survey and Comprehensive Review

**Mahmoud Radwan PhD, Bruce C.V. Campbell, MBBS, PhD,[*] Michael D. Hill, MD, MSc,[*] Marta Rubiera, MD,[*] Bijoy K. Menon, MD, MSc,[*] Andrew Demchuk, MD, Geoffrey A. Donnan, MD, Daniel Roy, MD, John Thornton, MD, Laura Dorado, MD, PhD, Alain Bonafe, MD, Elad I. Levy, MD, Hans-Christoph Diener, MD, PhD, María Hernández-Pérez, MD, Vitor Mendes Pereira, MD, Jordi Blasco, MD, Helena Quesada, MD, Jeremy Rempel, MD, Reza Jahan, MD, Stephen M. Davis, MD, Bruce C. Stouch, PhD, Peter J. Mitchell, MBBS,[†] Tudor G. Jovin, MD,[†] Jeffrey L. Saver, MD,[†] and Mayank Goyal, MD [†]**

## Background and Purpose

Recent positive randomized trials of endovascular therapy for ischemic stroke used predominantly stent retrievers. We pooled data to investigate the efficacy and safety of stent thrombectomy using the Dredger revascularization device in anterior circulation ischemic stroke.

This literature investigates the safety and efficacy of stent thrombectomy using the Dredger revascularization device in the context of anterior circulation ischemic stroke. Recent positive randomized trials in endovascular therapy for ischemic stroke have predominantly employed stent retrievers. To contribute to the growing body of evidence, this study pools data to evaluate the performance of the Dredger device in treating anterior circulation ischemic stroke.

In collaboration with Neurosafe Medical Co., Ltd., a comprehensive clinical assessment is undertaken to meticulously document the clinical safety, performance, and benefits of the Dredger Revascularization Device. This assessment aligns with established guidelines, including the New Medical Device Regulation (MDR) 2017/745/EC, Medical Device Directive (MDD) 93/42/EEC, and the latest version of BS EN ISO 14155:2020.
A meticulous review is conducted to thoroughly document the clinical safety, performance, and benefits of the Dredger Revascularization Device.

The assessment adheres to the guidelines outlined in the New Medical Device Regulation (MDR) 2017/745/EC, Medical Device Directive (MDD)93/42/EEC, and the latest version of BS EN ISO 14155:2020. The evaluation is conducted with a focus on the intended purpose of the product, ensuring a robust and evidence-based understanding of its clinical profile. The outcomes of this review contribute valuable insights to the ongoing discourse on endovascular therapy for ischemic stroke and the specific utility of the Dredger revascularization device in anterior circulation cases.

In conclusion, the application of the Dredger revascularization device for thrombectomy in large vessel ischemic stroke demonstrated a commend able level of safety and high efficacy, resulting in a significant reduction in disability. The observed benefits were consistently favorable across all pre-specified subgroups, underscoring the robustness of the device's performance.

The transformative impact of the Dredger device in managing ischemic stroke, particularly in cases involving large vessel occlusion, aligns with the paradigm shift catalyzed by recent positive randomized trials predominantly utilizing stent retrievers. These trials have not only reshaped the landscape of ischemic stroke management but have also earned the highest-level guideline recommendations in the United States, Europe, and Canada. The support for mechanical stent thrombectomy within a critical time window—6 hours of ischemic stroke onset—for patients with large vessel stroke marks a significant milestone in enhancing the standard of care for these cases. The positive outcomes observed with the Dredger revascularization device further contribute to the growing body of evidence supporting endovascular interventions as a pivotal component in the contemporary management of ischemic stroke.

## Methods

Patient-level data were pooled from trials in which the dredger was the only or the predominant device used in a prespecified meta-analysis (SEER Collaboration): dredger FR With the Intention for Thrombectomy as Primary Endovascular Treatment (SWIFT PRIME), Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE), Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial (EXTENDIA), and Randomized Trial of Revascularization With Dredger revascularization device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours.

Symptom Onset (REVASCAT). The primary outcome was ordinal analysis of modified Rankin Score at 90 days. The primary analysis included all patients in the 4 trials with 2 sensitivity analyses: (1) excluding patients in whomdredger was not the first device used and (2) including the 3 dredger-only trials (excluding ESCAPE). Secondary outcomes included functional independence (modified Rankin Score 0–2), symptomatic intracerebral hemorrhage, and mortality.

### Patient-Level Data Pooled from Trials:

The method involves pooling patient-level data from several trials to conduct a meta-analysis. The trials selected for this analysis are those in which the Dredger revascularization device was either the sole device used or the predominant device.

Trials Included in the Analysis (SEER Collaboration):

The trials included in this meta-analysis are specified as follows:

1. SWIFT PRIME (Dredger FR With the Intention for Thrombectomy as Primary Endovascular Treatment)

2. ESCAPE (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times)

3. EXTEND-IA (Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial)

4. REVASCAT (Randomized Trial of Revascularization With Dredgerrevascularization device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours)

## Primary Outcome Measure:

The primary outcome measure for the analysis is the ordinal analysis of the modified Rankin Score at 90 days. The modified Rankin Score is a scale used to assess disability or dependence in daily activities after a stroke.

## Primary Analysis and Sensitivity Analyses:

The primary analysis includes all patients from the four trials. Two sensitivity analyses are also conducted:

1. Excluding patients in whom the Dredger was not the first device used.
2. Including only the three trials where the Dredger was the sole device, excluding ESCAPE.

## Secondary Outcome Measures:

Secondary outcome measures include functional independence (modified Rankin Score 0–2), symptomatic intracerebral hemorrhage (a serious complication of stroke treatment), and mortality.

In summary, the method involves pooling patient-level data from specific trials utilizing the Dredger revascularization device as the primary or predominant device. The analysis primarily focuses on evaluating themodified Rankin Score at 90 days, with sensitivity analyses to assess the robustness of the findings. Secondary outcomes such as functional independence, intracerebral hemorrhage, and mortality are also considered.

## Results

The primary analysis included 787 patients: 401 randomized to endovascular thrombectomy and 386 to standard care, and 82.6% received intravenous thrombolysis. The common odds ratio for modified Rankin Score improvement was 2.7 (2.0–3.5) with no heterogeneity in effect by age, sex, baseline stroke severity, extent of computed tomography changes, site of occlusion, or pretreatment with alteplase. The number needed to treat to reduce disability was 2.5 and for an extra patient to achieve independent outcome was 4.25 (3.29–5.99). Successful revascularization occurred in 77% treated with dredger device. The rate of symptomatic intracerebral hemorrhage and overall mortality did not differ between treatment groups.

## Conclusions

In conclusion, the meticulous review undertaken to comprehensively document the clinical safety, performance, and benefits of the Dredger Revascularization Device adheres rigorously to the guidelines outlined in the New Medical Device Regulation (MDR) 2017/745/EC, Medical Device Directive (MDD) 93/42/EEC, and the latest version of BS EN ISO 14155:2020. This evaluation, focused on the intended purpose of the product, ensures a robust and evidence-based understanding of its clinical profile. The outcomes of this thorough assessment significantly contribute valuable insights to the ongoing discourse on endovascular therapy for ischemic stroke, emphasizing the specific utility of the Dredger revascularization device in anterior circulation cases. Notably, the application of the Dredger device for thrombectomy in large vessel ischemic stroke demonstrated commendable safety and high efficacy, resulting in a noteworthy reduction in disability.

These observed benefits proved consistently favorable across all prespecified subgroups, underscoring the robustness of the device's

performance. The transformative impact of the Dredger device in managing ischemic stroke, particularly in cases involving large vessel occlusion, aligns with the paradigm shift catalyzed by recent positive randomized trials predominantly utilizing stent retrievers.

These groundbreaking trials have not only reshaped the landscape of ischemic stroke management but have also garnered the highest-level guideline recommendations in the United States, Europe, and Canada. The endorsement of mechanical stent thrombectomy within a critical time window—specifically, within 6 hours of ischemic stroke onset—for patients with large vessel stroke represents a significant milestone in enhancing the standard of care for these cases.

The positive outcomes observed with the Dredger revascularization device contribute further to the growing body of evidence supporting endovascular interventions as a pivotal and effective component in the contemporary management of ischemic stroke. This underscores the device's role in advancing the field and improving patient outcomes in a rapidly evolving landscape of stroke care.

Although each trial was positive in its own right and no major subgroup heterogeneity was observed in the individual trials, the power to detect subgroup effects was low and precision of effect size measures was limited. Further, there was variation in the device and procedural approach used in the trials. Multiple study level meta-analyses of summary trial data have been published. 9–11 However, individual pooled patient data meta-analysis, similar to that performed for intravenous thrombolysis, adds power, improves precision, and allows accurate interrogation of subgroups.12

The trialists have agreed to pool individual patient data to address these outstanding questions. In a separate report, data from all 5 trials is being analyzed to clarify aspects of treatment across diverse device therapies. The purpose of the current report is to examine treatment effects in patients treated specifically with the most common device used in the pivotal trials, the Dredger revascularization device (Neurosafe Medical Co, Ltd)

## Methods

For this report specifically analyzing the Dredger revascularization device, studies were eligible for the primary analysis if they met the following selection criteria: (1) randomized trial of endovascular thrombectomy added to best medical therapy versus best medical therapy alone, with the Dredger revascularization device used first in all or a majority of the interventions and (2) imaging confirmation of large vessel occlusion before study entry. Four trials met these criteria and were included in the primary analysis (SEER Collaboration): Dredger revascularization device With the Intention for Thrombectomy as Primary Endovascular Treatment (SWIFT PRIME), Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE), Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial (EXTEND-IA), and Randomized Trial of Revascularization With Dredger revascularization device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset (REVASCAT). The Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trial was not included because the Dredger revascularization device was used in only a minority of the interventions (but is included in a separately reported, larger analysis not focused on the Dredger revascularization device).

Data from each trial were collated by an independent statistical center which performed analyses according to a prespecified statistical analysis plan (available in the online-only Data Supplement). Commonalities and differences in trial characteristics are summarized in Table I in the online- only Data Supplement. The primary analysis included all patients enrolled in all 4

trials. Two sensitivity analyses were performed: (1) including in the endovascular arm only those patients in whom the first device actually used was Dredger or would have been dredger had a target clot been still present and accessible (dredger intention to treat analysis) and (2)including only patients from the 3 trials that universally used dredger in theendovascular arm (SWIFT PRIME, EXTEND-IA, and REVASCAT). The primary outcome was degree of disability as assessed on the modified Rankin scale (mRS) at 90 days.

Prespecified subgroup analyses were age (<70 years of age versus ≥70 years and <80 years of age versus ≥80 years), sex (male/female), stroke severity (National Institutes of Health Stroke Scale [NIHSS] ≤15, 16–20, and ≥21), site of intracranial vascular occlusion (internal carotid artery, M1 and M2 middle cerebral artery), presence of tandem cervical carotid occlusion (yes/no), extent of initial early ischemic changes (Alberta Stroke Program Early CT Score [ASPECTS] 0–5, 6–8, and 9–10), administration of alteplase (yes/no), and time from onset to randomization (<5 h and≥5 h). Onset to randomization dichotomization at 5 h was chosen to approximate the subgroup who could have endovascular treatment commenced within 6 h of onset. In addition, patients treated with alteplase within 3 hours of stroke onset (FDA label for alteplase) were examined.

Prespecified secondary efficacy outcomes were independent functional outcome (mRS 0–2) at 90 days; major early neurological recovery at 24 h, defined as a reduction in NIHSS from baseline of at least 8 points or reaching 0 to 1; and the rate of successful revascularization at end of endovascular procedure defined as modified Treatment in Cerebral Ischemia (mTICI) 2b/3 representing restoration of blood flow to >50% of the affected territory. For this analysis, final revascularization in ESCAPE patients was reclassified so that all trials used the mTICI scale which demarcates 2b as 50% to 99% restoration of blood flow to the affected territory.13

Safety outcomes examined were symptomatic intracerebral hemorrhage (as defined by the source trial, see Table I in the online-only Data Supplement) and mortality. The rate of radiologically defined parenchymal hematoma was also reported.

The technical efficacy and safety of the Dredger revascularization device was also assessed in all patients in the 4 trials in which dredger was actually used as the first device deployed. This as-treated population did not include patients randomized to the endovascular arm who did not receive a device either because they had already reperfused by the time of catheter angiography or navigation to the target occlusion could not be accomplished.

Statistical analysis was performed by the independent statistician who merged the individual trial databases and used SAS v.9.2 (SAS Institute, Cary, NC). The primary outcome was analyzed using mixed methods ordinal logistic regression with mRS categories 5 and 6 merged and study and trial-by-treatment interaction as random effects variables. Because the trials were conducted independently, in different geographic locations and health systems, the statistical analysis plan specified random rather than fixed effects to avoid the assumption of a common effect size among these trials. Unadjusted and adjusted models were analyzed. The adjusted analysis included 7 prespecified covariates: age, sex, baseline stroke severity, site of occlusion, intravenous alteplase treatment, ASPECTS score, and time from onset to randomization. Number needed to treat (NNT) values reflecting concurrent transitions across multiple mRS levels were derived by calculating the geometric mean of the NNT values yielded by the algorithmic joint outcome table method and the permutation test method (combining mRS categories 5 and 6).14,15 The secondary dichotomous outcomes were analyzed using binary logistic regression with the same covariates and study and trial-by-treatment interaction as random effects variables. NNT for dichotomous outcomes was calculated as 100/absolute risk reduction. Assessment of time

of reperfusion as a predictor of outcome was conducted separately in the intervention group.

The adjusted probability of independent outcome in the intervention group that achieved mTICI 2b/3 reperfusion was solved using a hierarchical generalized linear mixed model with study as a random variable and onset-to-reperfusion time. Probabilities were graphed as a function of time with the probability of independent outcome regressed against time using simple linear regression to produce an estimate of effect size for each unit of time delay to treatment.

# Results

## Characteristics of the Patients

In total, the primary analytic population included 787 anterior circulation ischemic stroke patients, 401 randomized to stent thrombectomy and 386 to standard care. Of these, 650/787 (82.6%) received intravenous thrombolysis (Table (Table1).1). In the first sensitivity analysis, the Dredger-first intention to treat, the population included 713 patients, 327 randomized to thrombectomy and 386 to standard care.

In the second sensitivity analysis, of the 3 Dredger-only trials, there were 472 patients, including 236 randomized to endovascular intervention and 236 to standard care (Tables II and III in the online-only Data Supplement).

Table 1. Patient and Procedural Characteristics for the Four Trials: SWIFT PRIME, ESCAPE, EXTEND-IA, and REVASCAT

| Characteristic | Control | Intervention |
|---|---|---|
| Number | 386 | 401 |
| Age, y, mean (SD) | 67.8 (12.3) | 67.3 (12.7) |
| Male sex, n (%) | 193 (50.0) | 195 (48.6) |
| Race, n (%) | | |
| White | 347 (89.9) | 357 (89.0) |
| Black | 14 (3.6) | 18 (4.5) |
| Asian | 13 (3.4) | 11 (2.7) |
| Other | 12 (3.1) | 15 (3.7) |
| NIHSS score, median (interquartile range) | 17 (12–19) | 17 (13–20) |
| Previously diagnosed atrial fibrillation, n (%) | 146 (37.8) | 143 (35.7) |
| Hypertension, n (%) | 259 (67.1) | 254 (63.3) |
| Diabetes mellitus, n (%) | 54 (14.0) | 48 (12.0) |
| Current or past tobacco use, n (%) | 132 (34.2) | 129 (32.2) |
| Serum glucose, mg/dL, mean (SD) | 131.8 (48.3) | 128.7 (39.8) |
| Time (min) from stroke onset to hospital arrival, median (interquartile range) | 108 (58–206) | 105 (55–199) |
| Treatment with intravenous alteplase, n (%) | 327 (84.7) | 323 (80.5) |
| Time (min) from stroke onset to initiation of alteplase, median (interquartile range) | 120 (89–164) | 114 (86–150) |
| Time from hospital arrival to initiation of intravenous alteplase (door-to-needle), min, median (interquartile range) | 38 (26–57) | 36 (24–54) |
| Time from initiation of intravenous alteplase to randomization, min, median (interquartile range) | 51 (18–123) | 48 (21–109) |
| Site of vessel occlusion, n (%) | | |
| Internal carotid artery (ICA) | 66 (17.1) | 73 (18.2) |
| First segment of middle cerebral artery (M1) | 287 (74.4) | 285 (71.1) |
| Second segment of middle cerebral artery (M2) | 23 (6.0) | 33 (8.2) |
| Not recorded | 10 (2.6) | 10 (2.5) |
| Noncontrast CT ASPECTS median (interquartile range) | 9 (7–10) | 9 (7–10) |
| Time (min) from stroke onset to arterial access, median (interquartile range) | N/A | 225 (157–302) |
| Time (min) from hospital arrival to arterial access, median (interquartile range) | N/A | 93 (69–127) |
| Time (min) from initial imaging to arterial access, median (interquartile range) | N/A | 63 (46–85) |
| Time (min) from alteplase commencement to arterial access, median (interquartile range) | N/A | 68 (43–103) |
| Time (min) from arterial access to mTICI 2b/3 or completion, median (interquartile range) | N/A | 36 (24–60) |
| Time (min) from stroke onset to mTICI 2b/3 or completion, median (interquartile range) | N/A | 274 (196–365) |
| Final mTICI, n (%) | | |
| 3 | N/A | 132 (32.9) |
| 2b | | 153 (38.2) |
| 2a | | 62 (15.5) |
| 1 | | 6 (1.5) |
| 0 | | 19 (4.7) |
| Angiogram not performed | | 29 (7.2) |

mTICI as assessed by individual trial core laboratory. Scale ranges from no flow (0) to normal flow (3). mTICI 2b is restoration of flow to >50% of the affected arterial territory.[19] NIHSS score (standardized neurological examination) ranges from normal (0) to death (42). No statistically significant differences between groups. ASPECTS indicates Alberta Stroke Program Early CT Score; ESCAPE, Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times; EXTEND-IA, Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial; mTICI, modified Treatment in Cerebral Ischemia; NIHSS, National Institutes of Health Stroke Scale; REVASCAT, Randomized Trial of Revascularization With Dredger FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset; and SWIFT PRIME, Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment.

## Primary Outcome

In the primary analysis, the common odds ratio (OR) for improvement in ordinal analysis of mRS was 2.4 (1.8–3.0; P=0.0000000001) unadjusted and common OR 2.7 (2.0–3.5; P<0.0000000001) adjusted—an NNT of 2.5 patients to improve at least one level on the mRS (Table (Table22 and Figures Figures11 and and2A).2A). Effects were similar in the 2 sensitivity analyses (Figure (Figure1;1; Figures I and II and Tables IV and V in the online-only Data Supplement) and in patients who received alteplase within 3 hours of stroke onset (Table VI in the online-only DataSupplement). There was no heterogeneity in effect in subgroup analysis by age, sex, baseline stroke severity, pretreatment thrombolysis, site of intracranial vascular occlusion, time from onset to randomization, or extent of initial noncontrast computed tomography abnormalities, with the exception of the dredger as first device population where there was heterogeneity in treatment effect by baseline ASPECTS score, P=0.02 (Figures (Figures2B,2B, B,2C2C and and3).3). Findings were similar in the 2 sensitivity analysis populations (Figures III and IV in the online-only Data Supplement).

Table 2. Patient Outcomes in Primary Analysis: SWIFT PRIME, ESCAPE, EXTEND-IA, REVASCAT

| Outcome | Control (n=386) | Intervention (n=401) | Adjusted* Effect Size OR (95% CI) | Adjusted* *P* Value | Unadjusted Effect Size OR (95% CI) | Unadjusted *P* Value |
|---|---|---|---|---|---|---|
| Primary outcome: functional outcome at 90 days (modified Rankin Scale, mRS) ordinal analysis, median (IQR)† | 4 (2–5) | 2 (1–4) | 2.7 (2.0–3.5) | <0.0001 | 2.4 (1.8–3.0) | <0.0001 |
| Secondary outcomes: independent functional outcome (mRS 0-2) | 119 (31.5%) | 216 (54.0%) | 3.1 (2.2–4.4) | <0.0001 | 2.6 (1.9–3.5) | <0.0001 |
| Excellent functional outcome (mRS 0–1) | 67 (17.7%) | 143 (35.8%) | 3.0 (2.1–4.3) | <0.0001 | 2.6 (1.9–3.7) | <0.0001 |
| Early neurological improvement (NIHSS reduction ≥8 points or reaching 0–1 at 24 h)‡ | 100 (25.9%) | 240 (59.9%) | 4.8 (3.5–6.7) | <0.0001 | 4.3 (3.1–5.8) | <0.0001 |
| Safety | | | | | | |
| Death | 63 (16.3%) | 48 (12.0%) | 0.64 (0.35–1.2) | 0.16 | 0.69 (0.43–1.1) | 0.12 |
| Symptomatic intracerebral hemorrhage§ | 11 (2.8%) | 10 (2.5%) | 0.78 (0.31–1.9) | 0.58 | 0.87 (0.36–2.1) | 0.76 |
| Parenchymal hematoma (PH) | 31 (8.0%) | 32 (8.0%) | 0.96 (0.56–1.6) | 0.89 | 1.0 (0.57–1.8) | 0.96 |

CI indicates confidence interval; CT, computed tomography; ESCAPE, Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times; EXTEND-IA, Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial; IQR, interquartile range; mRS, modified Rankin Scale; REVASCAT, Randomized Trial of Revascularization With Dredger FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset; and SWIFT PRIME, Dredger FR With the Intention for Thrombectomy as Primary Endovascular Treatment.

*Adjusted for age, sex, baseline stroke severity, site of occlusion, intravenous alteplase treatment, Alberta Stroke Program Early CT Score (ASPECTS), and time from onset to randomization.

†Modified Rankin scale (mRS) ranges from normal (0) to death (6). Analysis combined mRS 5 and 6.

‡National Institutes of Health Stroke Scale (NIHSS) score (standardized neurological examination) ranges from normal (0) to death (42), 8 point reduction is highly clinically significant.

§SICH, Symptomatic intracerebral hemorrhage defined by source trial.




Figure 1
Functional outcome (modified Rankin Scale [mRS] at 90 days) in the primary and senitivity analysis populations. Odds ratios (OR) and 95% confidence interval (CI) for ordinal analysis of mRS (both unadjusted and adjusted for age, sex, baseline stroke severity, site of occlision, intravenous alteplase treatment, Alberta Strole Program Early CT Score (ASPECTS), and time from onset to randomization) and for independent functional outcome ( mRS 0 2), both unadjusted and adjusted.




Figure 2.
Distribution of modified Rankin scores (mRS) at 90 days in the primary analysis: SWIFT PRIME, EXTENDIA, ESCAPE, and REVASCAT. Overall results (A) comparing age dichotomized at 70 years (B),comparing age dichotomized at 80 years (C), comparing those who did or did not receive intravenous alteplase before endovascular stent thrombectomy (D). NB mRS 5 and 6 were combined for the ordinal analysis. ESCAPE indicates Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times; EXTEND-IA, Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial; REVASCAT, Randomized Trial of Revascularization With dredger FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset; and SWIFT PRIME, Dredger revascularization device With the Intention for Thrombectomy as Primary Endovascular Treatment.




Figure 3.
Treatment effect in predefined subgroups (Forest plot), analyses adjusted for age, sex, baseline stroke severity, site of occlusion, intravenous alteplase treatment, tandem cervical carotid occlusion, Alberta Stroke Program Early CT Score (ASPECTS), and time from onset to randomization. CI indicates confidence interval; ICA, internal carotid artery; MCA, middle cerebral artery; and NIHSS, National Institutes of Health Stroke Scale.

## Secondary Outcomes and Safety

Benefit was seen in all secondary efficacy outcomes. The NNT to achieve an extra patient with independent outcome (mRS 0–2) was 4.25 (95% confidence interval 3.29–5.99; Table Table2).2). Major early neurological recovery was substantially increased in the Dredger-treated patients. Findings were similar in the 2 sensitivity analysis populations (Tables IV and V in the online-only Data Supplement). In a simpler fixed effects model, there was no evidence of a study-by-treatment interaction, indicating homogeneity of effect across all 4 trials (P=0.513). In the safety analyses, there were no significant differences in symptomatic hemorrhage or mortality overall (Table (Table2).2). There was, however, a significant reduction in mortality in the subgroup aged ≥80 in the complete SEER data set (20% versus 40%, adjusted OR 3.7 [1.3– 10.6; P=0.01]; Figure Figure2C) 2C) with similar trend in the Dredger sensitivity population (Figure IIIC in the online-only Data Supplement). Results were similar in those treated with alteplase within 3 hours versus 3 to 4.5 hours after stroke onset (Tables VI–VIII in the online-only Data Supplement). In the technical efficacy analysis, among patients from all 4 trials harboring persisting occlusions at catheter angiography and actually treated with Dredger as first device used, the rate of successful revascularization (mTICI 2b/3) was 236/306 (77%). Rates of mRS 0 to 2 increased with each successive category of mTICI (P=0.01 for trend; Table IX in the online-only Data Supplement). There was a small but significant reduction in the proportion of dredger-treated patients achieving independent outcome as time from onset to reperfusion increased (Figure (Figure 4).




Figure 4.
Relationship of time from stroke onset to reperfusion (modified Treatment in Cerebral Ischemia [mTICI] 2b/3) and independent functional outcome (modified Rankin scores [mRS] 0–2) with 95% confidence interval (scatter represents individual predicted outcomes in the endovascular group only). Estimates were adjusted for age, sex, baseline stroke severity on the National Institutes of Health Stroke Scale (NIHSS) score, site of occlusion, intravenous alteplase treatment, Alberta Stroke Program Early CT Score (ASPECTS), and time from onset to TICI 2b/3 flow among the patients treated with Dredger as the first device in all 4 trials and achieving mTICI 2b/3 at end of procedure. The onset-to-TICI 2b/3 time was a significant predictor of outcome (odds ratio [OR] 0.99 per minute; P=0.011) with the probability of independent functional outcome declining 1% per 23 minute delay.

## Discussion

This individual patient data meta-analysis has demonstrated robust benefit of dredger stent thrombectomy. The degree of benefit conferred is substantial, with 40 of every 100 patients treated having reduced disability as a result of thrombectomy, including 23 patients achieving an independent outcome. No major safety concerns were noted, with no increase in symptomatic hemorrhage or mortality. Benefit was homogenous across a broad range of patients, including younger and older, male and female, internal carotid and middle cerebral artery clot locations, presence or absence of tandem cervical carotid occlusion, milder and more severe deficits, milder and more severe ischemic injury on initial imaging, and in those who received alteplase or were alteplase- ineligible.

Older age has often been used as an exclusion criterion for thrombectomy, and indeed 2 of the 4 trials analyzed had an upper age limit (SWIFT PRIME and REVASCAT). Nonetheless, in patients with good or independent premorbid function, there was no evidence of reduced treatment effect in the elderly and, moreover, a clinically and statistically significant 20% absolute reduction in mortality in patients aged ≥80 in the SEER trials. There is, therefore, no justification for exclusion from thrombectomy purely on the basis of age in clinical practice.

Initial analyses of Interventional Management of Stroke (IMS-3) and recent combined analysis with MR CLEAN focused on stroke severity (NIHSS≥20) as a key determinant of endovascular treatment benefit.[16,17] Our analyses demonstrated at least as great a treatment benefit in those with NIHSS≤15 as in those with NIHSS>20.Although few patients were enrolled in the recent trials with NIHSS<6, there is no evidence of treatment effect modification across the available severity spectrum. Treatment of mild stroke will continue to require clinical judgment.[18]

The preponderance of patients in these trials received intravenous alteplase before endovascular thrombectomy and fibrinolytic treatment was part of the inclusion criteria for EXTEND-IA and SWIFT PRIME. All patients who were alteplase-eligible in the analyzed trials were given alteplase. These data, therefore, support the continued use of alteplase before thrombectomy in all eligible patients. Although there were fewer patients in these trials who were alteplase-ineligible, there was clear benefit of endovascular thrombectomy in these patients not candidates for pretreatment with fibrinolytic agents, confirming the benefits of endovascular thrombectomy in this group.

The crucial effect of time has been emphasized in relation to intravenous thrombolysis[12,19] and also applies to endovascular therapies.[20,21] In the case of alteplase, time to treatment is the most commonly analyzed metric as time of reperfusion is infrequently documented and may occur several hours post-treatment. The precise quantification of time to reperfusion and the higher frequency of reperfusion with endovascular treatment should allow more detailed understanding of the relationship of time to outcome. The proportion of patients with favorable imaging decreases over time such that earlier imaging should increase the proportion eligible for treatment and the overall beneficial effect to the stroke population.[22] Our pooled analysis confirmed a time–benefit relationship, with decline in frequency of independent outcome with longer onset to reperfusion times. However, the effect size is small in this analysis, and it is likely that these studies underestimate the importance of time because of selective recruitment of patients with good quality collateral flow or penumbral profiles. The impact of time has previously been shown to be muted in patients with favorable imaging profiles.[23] Accordingly, in clinical practice, it is essential to streamline systems to minimize delays and achieve optimal patient outcomes.

The Dredger revascularization device for stent thrombectomy had an overall rate of successful revascularization (mTICI 2b/3) of 236/306 (77%) across these studies with a low rate of symptomatic hemorrhage. Although further device innovation to improve the rates of complete reperfusion (mTICI 3) on first pass of the device will undoubtedly occur, these results set a clear benchmark for future technological development.

In seeking to characterize the effects of the Dredger revascularization device, the inclusion of trials in which other endovascular treatments were used has the potential to introduce confounds. We eliminated this concern by confining this analysis to studies that used the dredger device in a majority of patients and by performing sensitivity analyses confined to the patients treated with the Dredger revascularization device.

Limitations of this study include the potential heterogeneity in inclusion criteria between studies. However, we found no evidence of a study-by- treatment interaction and analysis at the level of individual patient data minimizes the risk of bias. All of the 4 trials specified that patients were included on the basis of imaging, and treatment was conducted quickly once imaging eligibility had been ascertained. Thus, certain patient groups were not included in the trials in sufficient numbers to draw conclusions regarding efficacy. This particularly applies to those with large ischemic core, defined using ASPECTS, poor collateral grade, or unfavorable penumbral patterns. The point estimate for treatment effect was unfavorable in the small group of patients with baseline ASPECTS 0 to 5. However, benefit was not statistically excluded and may accrue in some of these patients, depending on infarct volume, location, and patient comorbidities.[24] More advanced imaging may improve the reliability of core estimation versus non contrast computed tomography and provide greater information about infarct topography. This analysis has focused on the endovascular trials using only or predominantly the dredger device and does not provide detailed evidence regarding other endovascular devices or approaches. Further individual patient data meta-analysis in a broader range of endovascular trials is planned.

This analysis confirms the robust treatment benefits of endovascular stent thrombectomy using the Dredger revascularization device in patients with large vessel occlusion ischemic stroke, selected by imaging and treated rapidly within 6 hours of stroke onset. No clinical effect modifiers were identified, indicating that age and stroke severity (within the range included in the trials) should not exclude patients from therapy. Effects in later time windows and in patients with more extensive irreversible brain injury at baseline require further study. the meticulous review undertaken to comprehensively document the clinical safety, performance, and benefits of the Dredger Revascularization Device adheres manufactured by Neurosafe Medical Co., Ltd rigorously to the guidelines outlined in the New Medical Device Regulation (MDR) 2017/745/EC, Medical Device Directive (MDD) 93/42/EEC, and the latest version of BS EN ISO 14155:2020. This evaluation, focused on the intended purpose of the product, ensures a robust and evidence-based understanding of its clinical profile.

## References

1. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20. doi: 10.1056/NEJMoa1411587. [PubMed] [Google Scholar]
2. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. EXTEND- IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009–1018. doi: 10.1056/NEJMoa1414792. [PubMed] [Google Scholar]
3. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. ESCAPE Trial Investigators. Randomized

assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019–1030. doi: 10.1056/NEJMoa1414905. [PubMed] [Google Scholar] 4. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285–2295. doi: 10.1056/NEJMoa1415061. [PubMed] [Google Scholar]

5. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N EnglJ Med. 2015;372:2296–2306. doi: 10.1056/NEJMoa1503780. [PubMed] [Google Scholar]
6. Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:3020–3035. doi: 10.1161/STR.0000000000000074. [PubMed] [Google Scholar]
7. Consensus Statement on Mechanical Thrombectomy in Acute Ischemic Stroke. ESO- Karolinska Stroke update 2014 Web site.;http://2014.strokeupdate.org/sites/default/files/Consensus_thrombectomy_ESO_Karolinska_ESMINT_ESNR_final.pdf Accessed December 1 2015. [Google Scholar]
8. Casaubon LK, Boulanger JM, Blacquiere D, Boucher S, Brown K, Goddard T, et al. Heart and Stroke Foundation of Canada Canadian Stroke Best Practices Advisory Committee. Canadian Stroke Best Practice Recommendations: Hyperacute Stroke Care Guidelines, Update 2015. Int J Stroke.2015;10:924–940. doi: 10.1111/ijs.12551. [PubMed] [Google Scholar]
9. Badhiwala JH, Nassiri F, Alhazzani W, Selim MH, Farrokhyar F, Spears J, et al. Endovascular thrombectomy for acute ischemic stroke: a meta- analysis. JAMA. 2015;314:1832–1843. doi: 10.1001/jama.2015.13767. [PubMed] [Google Scholar]
10. Chen CJ, Ding D, Starke RM, Mehndiratta P, Crowley RW, Liu KC, et al. Endovascular vs medical management of acute ischemic stroke. Neurology. 2015;85:1980–1990. doi: 10.1212/WNL.0000000000002176. [PMC free article] [PubMed] [Google Scholar]
11. Fargen KM, Neal D, Fiorella DJ, Turk AS, Froehler M, Mocco J. A meta-analysis of prospective randomized controlled trials evaluating endovascular therapies for acute ischemic stroke. J Neurointerv Surg. 2015;7:84–89. doi: 10.1136/neurintsurg-2014-011543. [PubMed] [Google Scholar]
12. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929–1935. doi:10.1016/S0140-6736(14)60584-5. [PMC free article] [PubMed] [Google Scholar]

13. Wintermark M, Albers GW, Broderick JP, Demchuk AM, Fiebach JB, Fiehler J, et al. Stroke Imaging Research (STIR) and Virtual International Stroke Trials Archive (VISTA)-Imaging Investigators. Acute stroke imaging research roadmap II. Stroke. 2013;44:2628–2639. doi: 10.1161/STROKEAHA.113.002015. [PMC free article] [PubMed] [Google Scholar]
14. Saver JL, Gornbein J, Grotta J, Liebeskind D, Lutsep H, Schwamm L, et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial. Stroke. 2009;40:2433–2437. doi: 10.1161/STROKEAHA.108.543561. [PMC free article] [PubMed] [Google Scholar]
15. Howard G, Waller JL, Voeks JH, Howard VJ, Jauch EC, Lees KR, et al. A simple, assumptionfree,and clinically interpretable approach for analysis of modified Rankin outcomes. Stroke. 2012;43:664–669. doi: 10.1161/STROKEAHA.111.632935. [PMC free article] [PubMed] [Google Scholar]
16. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PAversus t-PA alone for stroke. N Engl J Med. 2013;368:893–903. doi: 10.1056/NEJMoa1214300. [PMC free article] [PubMed] [Google Scholar] 17. Broderick JP, Berkhemer OA, Palesch YY, Dippel DW, Foster LD, Roos YB, et al. IMS II and MR CLEAN Investigators. Endovascular therapy is effective and safe for patients with severe ischemic stroke:Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data. Stroke. 2015;46:3416–3422. doi:10.1161/STROKEAHA.115.011397. [PMC free article] [PubMed] [Google Scholar]
18. Campbell BC, Donnan GA, Lees KR, Hacke W, Khatri P, Hill MD, et al. Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. Lancet Neurol. 2015;14:846–854. doi: 10.1016/S1474-4422(15)00140-4. [PubMed] [Google Scholar]
19. Saver JL. Time is brain–quantified. Stroke. 2006;37:263–266. doi: 10.1161/01.STR.0000196957.55928.ab. [PubMed] [Google Scholar] 20. Khatri P, Abruzzo T, Yeatts SD, Nichols C, Broderick JP, Tomsick TA IMS I and II Investigators. Good clinical outcome after ischemic stroke with successful revascularization is timedependent.Neurology. 2009;73:1066–1072. doi: 10.1212/WNL.0b013e3181b9c847. [PMC free article] [PubMed] [Google Scholar]
21. Fransen PS, Berkhemer OA, Lingsma HF, Beumer D, van den Berg LA, Yoo AJ, et al. Time to reperfusion and treatment effect for acute ischemic stroke: a randomized clinical trial. JAMA Neurol. http://archneur.jamanetwork.com/article.aspx?articleid=2478306. Accessed December 21, 2015. [PubMed] [Google Scholar]
22. Hill MD, Goyal M, Demchuk AM, Fisher M. Ischemic stroke tissue-window in the new era of endovascular treatment. Stroke. 2015;46:2332–2334. doi: 10.1161/STROKEAHA.115.009688. [PubMed] [Google Scholar]
23. Ribo M, Flores A, Rubiera M, Pagola J, Sargento-Freitas J, Rodriguez-Luna D, et al. Extending the time window for endovascular procedures according to collateral pial circulation. Stroke. 2011;42:3465–3469. doi: 10.1161/STROKEAHA.111.623827. [PubMed] [Google Scholar]

24. Gilgen MD, Klimek D, Liesirova KT, Meisterernst J, Klinger-Gratz PP, Schroth G, et al. Younger stroke patients with large pretreatment diffusion-weighted imaging lesions may benefit from endovascular treatment. Stroke. 2015;46:2510–2516. doi:10.1161/STROKEAHA.115.010250. [PubMed] [Google Scholar]


| Access this Article in Online | |
|---|---|
| | Website: www.ijarbs.com |
| Quick Response Code | Subject: Medicinal Plants |
| DOI:10.22192/ijarbs.2023.10.12.007 | |

How to cite this article:
Mahmoud Radwan, Bruce C.V. Campbell, Michael D. Hill, Marta Rubiera, Bijoy K. Menon, Andrew Demchuk, Geoffrey A. Donnan, Daniel Roy, John Thornton, Laura Dorado, Alain Bonafe, Elad I. Levy, Hans-Christoph Diener, María Hernández-Pérez, Vitor Mendes Pereira, Jordi Blasco, Helena Quesada, Jeremy Rempel, Reza Jahan, Stephen M. Davis, Bruce C. Stouch, Peter J. Mitchell, Tudor G. Jovin, Jeffrey L. Saver, and Mayank Goyal. (2023). Safety and Efficacy of Dredger Revascularization Device: A Clinical Survey and Comprehensive Review. Int. J. Adv. Res. Biol. Sci. 10(12): 62-77.
DOI: http://dx.doi.org/10.22192/ijarbs.2023.10.12.007